tirzepatide heart failure Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure

In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Full trial results and Plain Language Summary: https://t.co/8joe2mst3e

23.99

★★★★☆4.8 (126)

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

24.30

★★★★★4.9 (98)

Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis

24.22

★★★★★5.0 (157)

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism

26.90

★★★★★4.7 (84)

Tirzepatide, initially approved for Type 2 diabetes and weight management, is emerging as a promising treatment for heart failure. Recent studies indicate that it not only reduces the risk of heart…

21.87

★★★★★4.9 (203)

🔴Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up than 2 previous trials with semaglutide ⤵️ #AHA24 🔹In patients with heart failure with preserved

21.97

★★★★★5.0 (176)

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM 🥸The SUMMIT trial

27.18

★★★★★4.8 (132)